Interstitial Cystitis News Around the Web

• Uro Today:

Neuromodulation 10 Years On: How Widely Should We Use This Technique in Bladder Dysfunction? – Abstract

There has been growing interest in sacral nerve stimulation in the management of both overactivity syndromes and nonobstructive voiding dysfunction. Its increased use has led to a growth in experience with this treatment and where and when it is best used. At this point, some technical aspects of the use of neuromodulation have become more standardized and the next stages of research will hopefully shed light on how to maximize the efficacy of the technique.

Interstitial Cystitis is an Etiology of Chronic Pelvic Pain in Young Women – Abstract

The prevalence of interstitial cystitis (IC) in young women, especially in those 18 years old or younger, is not well defined. This case series was performed to investigate IC as a cause of chronic pelvic pain (CPP) in young women. Design: Case series. Setting: University medical center.

Neuromodulation and Female Sexual Function: Does Treatment for Refractory Voiding Symptoms Have An Added Benefit? – Abstract

Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF).  Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months.

Urinary Nerve Growth Factor Level is Increased in Patients With Interstitial Cystitis/Bladder Pain Syndrome and Decreased in Responders to Treatment – Abstract

 To measure urinary nerve growth factor (NGF) levels in patients with interstitial cystitis/bladder pain syndrome (IC/BPS), and to evaluate the role of urinary NGF in predicting the response to treatment, as the clinical diagnosis of IC/BPS is based on subjective symptoms and recent investigations suggest that urinary NGF is increased in patients with IC/BPS.

TARIS Biomedical Launches with $15 Million in Funding to Develop Innovative Drug-Device Therapies

TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, launched today and announced it has secured $15 million in Series A financing. Leading venture capital firms Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners co-led the investment in TARIS, which was founded by internationally renowned scientists from the Massachusetts Institute of Technology (MIT), Michael Cima, Ph.D. and Robert Langer, Ph.D., along with Christine Bunt, Chief Operating Officer and former executive with CombinatoRx, Merck & Co and Hoffmann La-Roche.

Bio Space

Allergy treatment helps some cystitis

Two U.S. physicians suggest allergy testing may help some who suffer from the painful bladder condition interstitial cystitis. Dr. John Hubbard, a urologist, and Dr. C. Steven Smith, an allergist/immunologist, both in Louisville, Ky., said that they have had positive results for interstitial cystitis after allergy testing and treatment.

UPI.com